Compare RC & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RC | RNA |
|---|---|---|
| Founded | 2007 | 2012 |
| Country | United States | United States |
| Employees | 442 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 257.3M | 217.5M |
| IPO Year | N/A | 2025 |
| Metric | RC | RNA |
|---|---|---|
| Price | $1.99 | $14.38 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 20 |
| Target Price | $2.81 | ★ $69.26 |
| AVG Volume (30 Days) | ★ 1.6M | 370.2K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.16% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $88.12 |
| Revenue Next Year | $67.36 | $18.11 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.50 | $11.95 |
| 52 Week High | $4.75 | $73.06 |
| Indicator | RC | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 70.45 | 28.92 |
| Support Level | $1.97 | $12.85 |
| Resistance Level | $2.15 | $72.75 |
| Average True Range (ATR) | 0.08 | 0.59 |
| MACD | 0.05 | 1.52 |
| Stochastic Oscillator | 100.00 | 81.20 |
Ready Capital Corp is a real estate finance company that originates, acquires, finances, and services LMM loans, SBA loans, construction loans, USDA loans and, to a lesser extent, MBS collateralized mainly by LMM loans or other real estate-related investments. Its loans are used by businesses to purchase real estate used in their operations or by investors seeking to acquire multi-family, office, retail, mixed use or warehouse properties. It operates through two segments: LMM Commercial Real Estate, which originates LMM loans across the life-cycle of an LMM property including construction, bridge, stabilized and agency loan channels, and Small Business Lending, which acquires, originates and services owner-occupied loans guaranteed by the SBA and also originates and services USDA loans.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.